Treatment Details – 6.0 months
|Patients: This Phase II study involved 105 patients with unresectable malignant mesothelioma.|
Treatment: The treatment consisted of administration of the drug ranpirnase (onconase).
Toxicity: There were ten deaths during the study and eleven deaths within 30 days of the last dose of treatment. The authors, however, concluded, that there no serious adverse events or deaths related to ranpirnase treatment. Grade 3 or 4 toxicities included hypotension, anaphylactoid reaction, worsening of lupus symptoms, kidney function abnormalities, asthenia, edema, arthralgia, pain, anorexia, nausea, myalgia, flu syndrome, and neuropathy.
Results: The overall median survival time was 6 months.
Support: The study was supported by Alfacell Corporation and two of the study’s authors work for Alfacell. Alfacell markets ranpirnase.
Correspondence: Stanislaw Mikulski